OPEN Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Published online: 30 August 2021

Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang & Gee-Chen Chang

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-021-91657-7>, published online 08 June 2021

The original version of this Article contained errors in Table 4, where the P value was omitted and the “Adjusted HR (95% CI)^a” value for “ECOG PS” was incorrectly assigned. The correct and incorrect values appear below.

Incorrect:

Characteristics	HR (95% CI) ^a	P value	Adjusted HR (95% CI) ^a	P value
Smoking status				
NS	Reference		0.51 (0.29–0.90)	
C/FS	1.59 (0.95–2.65)	0.079		
ECOG PS				
2–4	Reference			
0–1	0.52 (0.30–0.90)	0.019		

Correct:

Characteristics	HR (95% CI) ^a	P value	Adjusted HR (95% CI) ^a	P value
Smoking status				
NS	Reference			
C/FS	1.59 (0.95–2.65)	0.079		
ECOG PS				
2–4	Reference			
0–1	0.52 (0.30–0.90)	0.019	0.51 (0.29–0.90)	0.020

The original Article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021